Adenosine receptor modeling: what does the A2A crystal structure tell us?

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Current Topics in Medicinal Chemistry

• Publication date

  2010-06-30

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/156802610791293145PMID 20370656
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands.

  2009influential reference
• N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice.

  2009cited by this paper
• Molecular docking study of A(3) adenosine receptor antagonists and pharmacophore-based drug design.

  2009cited by this paper
• Adenosine A2A Receptor Antagonists: New 8‐Substituted 9‐Ethyladenines as Tools for in vivo Rat Models of Parkinson's Disease

  2009cited by this paper
• Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.

  2009cited by this paper
• Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure.

  2009influential reference
• Topology of Class A G Protein-Coupled Receptors: Insights Gained from Crystal Structures of Rhodopsins, Adrenergic and Adenosine Receptors

  2009cited by this paper
• Homology modelling of the human adenosine A2B receptor based on X-ray structures of bovine rhodopsin, the β2-adrenergic receptor and the human adenosine A2A receptor

  2009influential reference
• Novel potent and highly selective human A(3) adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: molecular docking analysis and pharmacological studies.

  2009cited by this paper
• Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system.

  2009influential reference
• Molecular modeling of A1 and A2A adenosine receptors: Comparison of rhodopsin‐ and β2‐adrenergic‐based homology models through the docking studies

  2009influential reference
• 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.

  2009cited by this paper
• Molecular modeling of a PAMAM-CGS21680 dendrimer bound to an A2A adenosine receptor homodimer.

  2008cited by this paper
• Probing distal regions of the A2B adenosine receptor by quantitative structure-activity relationship modeling of known and novel agonists.

  2008cited by this paper
• The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist

  2008influential reference
• Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists.

  2008cited by this paper
• Structure of a β1-adrenergic G-protein-coupled receptor

  2008cited by this paper
• Linear and Nonlinear 3D-QSAR Approaches in Tandem with Ligand-Based Homology Modeling as a Computational Strategy To Depict the Pyrazolo-Triazolo-Pyrimidine Antagonists Binding Site of the Human Adenosine A2A Receptor

  2008cited by this paper
• Structure-activity relationship studies of a new series of imidazo[2,1-f]purinones as potent and selective A(3) adenosine receptor antagonists.

  2008cited by this paper
• Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system.

  2008cited by this paper
• Selective Human Adenosine A3 Antagonists based on Pyrido[2,1‐f]purine‐2,4‐diones: Novel Features of hA3 Antagonist Binding

  2008influential reference
• Substituted Pyrazolo[3,4‐b]pyridines as Potent A1 Adenosine Antagonists: Synthesis, Biological Evaluation, and Development of an A1 Bovine Receptor Model

  2008cited by this paper
• Molecular modeling of adenosine receptors: new results and trends

  2008cited by this paper
• A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor.

  2008cited by this paper
• A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists.

  2008cited by this paper
• High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.

  2007cited by this paper
• Basic Concepts in G-Protein-Coupled Receptor Homo- and Heterodimerization

  2007cited by this paper
• Highlights on the Development of A2A Adenosine Receptor Agonists and Antagonists

  2007cited by this paper
• GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function

  2007cited by this paper
• Probing the binding site of the A1 adenosine receptor reengineered for orthogonal recognition by tailored nucleosides.

  2007influential reference
• 3-Dimensional structures of G protein-coupled receptors and binding sites of agonists and antagonists.

  2007cited by this paper
• Structure and Function of G Protein-Coupled Receptors Studied Using Sequence Analysis, Molecular Modeling and Receptor Engineeri

  2007cited by this paper
• Computational studies of Family A and Family B GPCRs.

  2007cited by this paper
• 5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists.

  2007cited by this paper
• Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study.

  2007cited by this paper
• Synthesis, biological activity and molecular modelling of new trisubstituted 8-azaadenines with high affinity for A1 adenosine receptors.

  2007cited by this paper
• High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor

  2007influential reference
• New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.

  2007cited by this paper
• N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor.

  2007cited by this paper
• ZM241385, DPCPX, MRS1706 Are Inverse Agonists with Different Relative Intrinsic Efficacies on Constitutively Active Mutants of the Human Adenosine A2B Receptor

  2007cited by this paper
• Crystal structure of the human β2 adrenergic G-protein-coupled receptor

  2007cited by this paper
• Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes

  2007cited by this paper
• Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor.

  2007cited by this paper
• Crystal structure of the human beta2 adrenergic G-protein-coupled receptor.

  2007cited by this paper
• Computer aided comparative analysis of the binding modes of the adenosine receptor agonists for all known subtypes of adenosine receptors.

  2007influential reference
• Human cytidine deaminase: a three-dimensional homology model of a tetrameric metallo-enzyme inferred from the crystal structure of a distantly related dimeric homologue.

  2006cited by this paper
• Computational prediction of homodimerization of the A3 adenosine receptor.

  2006influential reference
• Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor.

  2006influential reference
• Pharmacophore based receptor modeling : The case of adenosine A3 receptor antagonists. An approach to the optimization of protein models

  2006cited by this paper
• Molecular modelling study of 2-phenylethynyladenosine (PEAdo) derivatives as highly selective A3 adenosine receptor ligands

  2006cited by this paper
• Molecular dynamics simulation of the human adenosine A3 receptor: agonist induced conformational changes of Trp243

  2006cited by this paper
• 2-triazole-substituted adenosines: a new class of selective A3 adenosine receptor agonists, partial agonists, and antagonists.

  2006cited by this paper
• Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models.

  2006cited by this paper
• A role for information collection, management, and integration in structure-function studies of G-protein coupled receptors.

  2006cited by this paper
• Induced fit and pharmacophore generation approach applied to A2A adenosine receptor antagonists

  2006influential reference
• 4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.

  2006cited by this paper
• Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.

  2006cited by this paper
• Progress in the pursuit of therapeutic adenosine receptor antagonists

  2006cited by this paper
• Adenosine receptor modelling. A1/A2a selectivity.

  2006influential reference
• Ligand-based homology modeling as attractive tool to inspect GPCR structural plasticity.

  2006cited by this paper
• Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists.

  2006cited by this paper
• Homology modeling of G-protein-coupled receptors and implications in drug design.

  2006cited by this paper
• Computational methods in drug design: Modeling G protein-coupled receptor monomers, dimers, and oligomers

  2006cited by this paper
• Inactive and active states and supramolecular organization of GPCRs: insights from computational modeling

  2006cited by this paper
• Role of the second transmembrane domain of rat adenosine A1 receptor in ligand-receptor interaction.

  2006cited by this paper
• Latest development in drug discovery on G protein-coupled receptors.

  2006cited by this paper
• The study of G‐protein coupled receptor oligomerization with computational modeling and bioinformatics

  2005cited by this paper
• Techniques: Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example.

  2005cited by this paper
• Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.

  2005cited by this paper
• 1,2,4-Triazolo[1,5-a]quinoxaline as a Versatile Tool for the Design of Selective Human A3 Adenosine Receptor Antagonists: Synthesis, Biological Evaluation, and Molecular Modeling Studies of 2-(Hetero)aryl- and 2-Carboxy-Substitued Derivatives

  2005cited by this paper
• A "locked-on," constitutively active mutant of the adenosine A1 receptor.

  2005cited by this paper
• Synthesis, biological and modeling studies of 1,3-di-n-propyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as adenosine receptor antagonists.

  2005cited by this paper
• Computational modeling approaches to structure-function analysis of G protein-coupled receptors.

  2005cited by this paper
• Molecular modeling and molecular dynamics simulation of the human A2B adenosine receptor. The study of the possible binding modes of the A2B receptor antagonists.

  2005influential reference
• New prospects for drug discovery from structural studies of rhodopsin.

  2005cited by this paper
• A neoceptor approach to unraveling microscopic interactions between the human A2A adenosine receptor and its agonists.

  2005cited by this paper
• Nucleoside Modification and Concerted Mutagenesis of the Human A3 Adenosine Receptor to Probe Interactions Between the 2-Position of Adenosine Analogs and Gln167 in the Second Extracellular Loop

  2005cited by this paper
• 1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.

  2005cited by this paper
• Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study.

  2005cited by this paper
• GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support

  2005cited by this paper
• Comparative Analysis of Putative Agonist‐Binding Modes in the Human A1 Adenosine Receptor

  2004influential reference
• Purine receptors: GPCR structure and agonist design.

  2004cited by this paper
• 1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.

  2004cited by this paper
• The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure.

  2004cited by this paper
• Novel approaches for modeling of the A1 adenosine receptor and its agonist binding site

  2004influential reference
• Random mutagenesis of the human adenosine A2B receptor followed by growth selection in yeast. Identification of constitutively active and gain of function mutations.

  2004influential reference
• Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique adenosine derivative.

  2004cited by this paper
• Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function.

  2004cited by this paper
• Structure-activity relationships of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists.

  2004cited by this paper
• Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position.

  2004cited by this paper
• Exploring distal regions of the A3 adenosine receptor binding site: sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands.

  2004cited by this paper
• Exploring the molecular basis of selectivity in A1 adenosine receptors agonists: a case study

  2003influential reference
• Modeling the 3D structure of GPCRs: advances and application to drug discovery.

  2003cited by this paper
• Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor.

  2003influential reference
• Purine and deazapurine nucleosides: synthetic approaches, molecular modelling and biological activity.

  2003cited by this paper
• The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints.

  2003cited by this paper
• Organization of the G Protein-coupled Receptors Rhodopsin and Opsin in Native Membranes*

  2003cited by this paper
• Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.

  2003cited by this paper
• Adenosine A2A-Dopamine D2 Receptor-Receptor Heteromerization

  2003cited by this paper
• Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists.

  2003influential reference

• Structure-Activity Relationship Analysis of 2-Aryl-8-alkynyl Adenine and Nucleoside Scaffolds as A3 Adenosine Receptor Ligands.

  2025cites this paper
• Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics of ligands targeting G-protein-coupled receptors

  2022cites this paper
• Non-Nucleoside Agonists of the Adenosine Receptors: An Overview

  2019cites this paper
• Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain.

  2019cites this paper
• New A2A adenosine receptor antagonists: a structure-based upside-down interaction in the receptor cavity.

  2019cites this paper
• Targeting adenosine A2A receptor antagonism for treatment of cancer

  2018cites this paper
• The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor.

  2018cites this paper
• New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases.

  2018cites this paper
• Discovery of Novel Adenosine Receptor Antagonists through a Combined Structure- and Ligand-Based Approach Followed by Molecular Dynamics Investigation of Ligand Binding Mode

  2018cites this paper
• Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes.

  2017cites this paper
• The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype.

  2017cites this paper
• Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors.

  2016cites this paper
• The Length and Flexibility of the 2‐Substituent of 9‐Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor

  2016cites this paper
• Biochemical and biophysical studies on adenosine receptors and their interaction partners

  2016cites this paper
• Simulation and Comparative Analysis of Different Binding Modes of Non‐nucleoside Agonists at the A2A Adenosine Receptor

  2016cites this paper
• Discovery of aminoquinazoline derivatives as human A(2A) adenosine receptor antagonists.

  2016cites this paper
• New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists

  2015cites this paper
• Mutation-Guided Unbiased Modeling of the Fat Sensor GPR119 for High-Yield Agonist Screening.

  2015cites this paper
• 1,2,4-triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A₃ receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies.

  2015cites this paper
• Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation.

  2015cites this paper
• Development of [18F]-labeled pyrazolo[4,3-e]-1,2,4- triazolo[1,5-c]pyrimidine (SCH442416) analogs for the imaging of cerebral adenosine A2A receptors with positron emission tomography.

  2014cites this paper
• Development and preclinical evaluation of radioligands for the PET studies of cerebral adenosine A1 and A2A receptors

  2014cites this paper
• Structure‐Based and Fragment‐Based GPCR Drug Discovery

  2014cites this paper
• Synthesis and Anti-Renal Fibrosis Activity of Conformationally Locked Truncated 2-Hexynyl-N6-Substituted-(N)-Methanocarba-nucleosides as A3 Adenosine Receptor Antagonists and Partial Agonists

  2014cites this paper
• Molecular modeling of adenosine receptors.

  2013cites this paper
• Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor

  2013cites this paper
• Synthesis, biological activity and molecular modelling studies of tricyclic alkylimidazo-, pyrimido- and diazepinopurinediones

  2013cites this paper
• Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists: synthesis, structure-affinity relationships and molecular modeling studies.

  2013cites this paper
• Stabilised G protein-coupled receptors in structure-based drug design: a case study with adenosine A2A receptor

  2013cites this paper
• Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design

  2012cites this paper
• G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions

  2012cites this paper
• Purinergic signalling: what is missing and needed next? The use of transgenic mice, crystallographic analysis and MicroRNA.

  2012cites this paper
• Identification of Novel Adenosine A2A Receptor Antagonists by Virtual Screening

  2012cites this paper
• The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors.

  2011cites this paper
• The use of GPCR structures in drug design.

  2011cites this paper
• Synthesis, structure-affinity relationships, and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists.

  2011cites this paper
• Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine.

  2011influential citation
• Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation

  2011cites this paper
• Biophysical Mapping of the Adenosine A2A Receptor

  2011cites this paper
• Progress in Structure Based Drug Design for G Protein-Coupled Receptors

  2011cites this paper
• Molecular modeling study on potent and selective adenosine A(3) receptor agonists.

  2010cites this paper
• Different Binding Modes of Structurally Diverse Ligands for Human D3DAR

  2010cites this paper
• Resource Mutation-Guided Unbiased Modeling of the Fat Sensor GPR 119 for High-Yield Agonist Screening Graphical Abstract Highlights

  year unknowncites this paper